Are you treating ypN0 patient with adjuvant abemaciclib? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37079950/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions/Relevance: These considerations highlight the need for a proper clinical staging on locoregional lymph nodes at the diagnosis of disease and the importance of looking for cytological confirmation of all suspect nodes. All these additional criteria shall be stressed and spread to avoid missing any patient that could benefit from an...
-
Albert Dekker2yrI don't and I find the compound difficult in adjuvant setting
Controlling cell proliferation by targeting cyclin-dependent kinase 6 using drug repurposing approach
Source : https://www.sciencedirect.com/science/article/abs/pii/S1876162323000123?via=ihub
Cyclin-dependent kinase 6 (CDK6) is an essential kinase in cell cycle progression, which is a viable target for inhibitors in various malignancies, including breast cancer. This study aimed to virtually...
Conclusions/Relevance: The selected two compounds are small molecules in the appropriate druglikeness range. The results observed in molecular docking and molecular dynamics simulations were most promising for two compounds, suggesting their potent inhibitory effect against CDK6. We propose that these candidate compounds can undergo in vitro...
-
Albert Dekker2yrhopefully agents will make to clinical practice fast
The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates
Source : https://cdrjournal.com/article/view/5386
Human epidermal growth factor receptor 2 protein (HER2)-positive breast cancer is an aggressive disease that accounts for approximately 15%-20% of the total breast cancer cases worldwide. Most of these cases...
Conclusions/Relevance: Advances in the design of antibody-drug conjugates have led to the development of new generation drugs with enhanced properties, such as trastuzumab deruxtecan and trastuzumab duocarmazine, which are significantly changing the paradigm in the treatment of HER2-positive metastatic breast cancer.
-
Albert Dekker2yrclearly new ADC are very effective
Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting
Source : https://www.sciencedirect.com/science/article/abs/pii/S1876162323000135?via=ihub
Regulated cell division is one of the fundamental phenomena which is the basis of all life on earth. Even a single base pair mutation in DNA leads to the production...
Conclusions/Relevance: In this chapter, we discuss the molecular mechanism through which cyclins and CDKs regulate cell cycle progression and the emergence of cyclins and CDKs as rational targets in cancer. We also discuss recent advances in developing CDK inhibitors, which have emerged as a novel class of inhibitors, and their associated...
Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37038927/
The therapeutic paradigm of breast cancer involving CDK4/6 inhibitors presents some still open discussion points. Further evidence regarding the best treatment strategy in HR+ HER2- metastatic breast cancer and the...
Expert opinion: The therapeutic paradigm of breast cancer involving CDK4/6 inhibitors presents some still open discussion points. Further evidence regarding the best treatment strategy in HR+ HER2- metastatic breast cancer and the efficacy of CDK 4/6is in the early stage will be necessary in the next future. Predictive biomarkers of response...